Jefferies Group's IONS Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 50,395 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $3.99 M, representing 0.02% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2023, adding 93,000 shares. Largest reduction occurred in Q1 2023, reducing 197,009 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +40,226 | Add 395.57% | 50,395 | $79.11 |
| Q3 2025 | -12,212 | Reduce 54.56% | 10,169 | $65.42 |
| Q2 2025 | -460 | Reduce 2.01% | 22,381 | $39.51 |
| Q1 2025 | +460 | Add 2.06% | 22,841 | $30.17 |
| Q4 2024 | -30,400 | Reduce 57.60% | 22,381 | $34.96 |
| Q3 2024 | -9,419 | Reduce 15.14% | 52,781 | $40.06 |
| Q2 2024 | -130,880 | Reduce 67.79% | 62,200 | $47.66 |
| Q1 2024 | -9,220 | Reduce 4.56% | 193,080 | $43.35 |
| Q4 2023 | +42,090 | Add 26.27% | 202,300 | $50.59 |
| Q3 2023 | +67,210 | Add 72.27% | 160,210 | $45.36 |
| Q2 2023 | +93,000 | New Buy | 93,000 | $41.03 |
| Q1 2023 | -197,009 | Sold Out | 0 | $0.00 |
| Q4 2022 | +197,009 | New Buy | 197,009 | $37.77 |
Jefferies Group's Ionis Pharmaceuticals Investment FAQs
Jefferies Group first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2022, acquiring 197,009 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Ionis Pharmaceuticals, Inc. (IONS) for 13 quarters since Q4 2022.
Jefferies Group's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q4 2022, adding 197,009 shares worth $7.44 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 50,395 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $3.99 M.
As of the Q4 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 202,300 shares, as reported at the end of Q4 2023.